Navigation Links
Benefit of PET in patients with head and neck tumors cannot be assessed
Date:4/29/2011

The benefit and harm of positron emission tomography (PET) in patients with head and neck tumours, applied alone or in combination with computed tomography (CT), cannot currently be reliably assessed. This is the result of a final report published by the German Institute for Quality and Efficiency in Health Care (IQWiG). The Institute was commissioned by the Federal Joint Committee (G-BA) to assess the advantages and disadvantages of this diagnostic method. However, as the authors of the report explain, suitable studies for this purpose are lacking.

Tobacco and alcohol are important risk factors

Various types of cancer are summarized under the term "head and neck tumours". Among others, these are malignant tumours of the oral cavity (lips, tongue etc.), the pharynx, the larynx, the nose and paranasal sinuses, as well as the outer neck. In Germany about 20,000 people per year develop a malignant head and neck tumour. Men are affected about three times more often than women. In German men, cancer of the oral cavity and pharynx is the seventh most common type of cancer. The consumption of tobacco and alcohol are important risk factors. Prospects of cure vary, depending on the localization of the cancer. For example, the 5-year survival rate in patients with lip tumours is over 90%, whereas in those with pharyngeal tumours the rate is only 30-40%.

PET makes increased metabolic activity visible

By using PET, doctors hope to improve the diagnosis of tumours and the determination of exact tumour expansion. Treatment (e.g. of metastases) could then be targeted more accurately than after the application of other diagnostic techniques. Conventional imaging methods such as computed tomography (CT) show the structure and location of healthy and abnormal tissue. Beyond this, PET can measure metabolic activity in the tissue. The PET image indicates areas of increased metabolic activity in the body by means of a weak radioactive substance. However, such changes can have many other causes; for example, metabolic activity is also increased if tissue is inflamed.

With so-called integrated devices (PET/CT) the patient undergoes a CT and PET in one investigation in which he or she is transported through a tube that includes both systems (two detector ring systems). The images produced are fused together in a computer.

Only consequences tangible for the patient are classified as a benefit

As, from a medical point of view, an additional test is only meaningful if it leads to an improvement in treatment, IQWiG primarily assessed whether the potentially greater diagnostic accuracy of PET or PET/CT also has an impact on the success of treatment for a head and neck tumour. In this context, events that had tangible consequences for patients were classified as having a benefit. For example, a benefit exists if mortality rates are lower, patients experience fewer recurrences or have a higher quality of life, or PET better supports decision-making on the choice of correct treatment than do other diagnostic techniques.

In the benefit assessment IQWiG considered studies with or without random allocation of study participants to treatment groups (randomization). However, they identified only one study directly investigating the benefit of PET. This study included a small number of participants and, due to methodological deficits, was susceptible to bias.

Benefit neither proven nor refuted

In a direct comparison, this study investigated a diagnostic-therapeutic strategy with and without PET. However, for the primary outcome of this study (2-year recurrence-free survival) no difference between groups could be demonstrated. However, the number of participants (102) and recurrences experienced (6 with PET and 4 without PET) was very small. On the basis of these study results, a patient-relevant benefit of PET can neither be proven nor refuted.

No proven advantages of PET for diagnostic accuracy

The second research question of the report was whether by means of PET or PET/CT it can be determined more reliably than with conventional diagnostic techniques what stage the tumour has reached ("staging"), whether it responds to treatment and can ultimately be treated successfully, as well as whether the disease (in the case of justified suspicion) has actually reappeared ("recurrence"). It was also investigated whether by means of PET or PET/CT the tumour search is improved in patients with an unknown primary tumour. These are patients with head and neck metastases, the origin of which is unknown.

These questions are summarized under the term "diagnostic accuracy", which is the ability of a test to distinguish correctly between sick and healthy patients. However, studies that only investigate diagnostic accuracy do not allow conclusions about the benefit for patients. This is because greater diagnostic accuracy does not automatically lead to the choice of a more targeted therapy or to an increase in quality of life or a decrease in mortality rates.

A larger number of studies were available on this topic; however, their informative value was shown to be greatly limited. This is due to the fact that, on the one hand, the number of participants per study was low and, on the other, the studies were planned or conducted in such way that bias could not be excluded or was even probable.

Overall, in the comparison of PET with CT, no technology was superior to another. PET identifies new tumours relatively accurately, but also is often the cause of false alarms. However, here too the results were ultimately of insufficient informative value.

Researchers call for further studies

In view of this unsatisfying evidence base, overall the authors of the report see a substantial need for improvement in the planning, conduct and reporting of diagnostic studies. They also call for additional studies. This is because PET may have advantages, especially in the diagnosis of recurrences and unknown primary tumours.

However, this would urgently demand further investigation, primarily requiring studies that directly compare PET/CT with the current diagnostic standard (e.g. CT or MRT). Even if PET/CT showed higher diagnostic accuracy here, it would still need to be proved that patients have a tangible benefit from the more reliable diagnosis, for example by surviving longer or having a better quality of life. Such proof can in principle only be provided by means of randomized controlled trials.


'/>"/>

Contact: IQWiG
info@iqwig.de
49-022-135-6850
Institute for Quality and Efficiency in Health Care
Source:Eurekalert

Related medicine news :

1. Frequently hospitalized patients may benefit from new medical specialty focused on their needs
2. Group Visits With Doctor May Benefit Parkinsons Patients
3. Phase 3 trial finds no benefit from atrasentan added to chemo for advanced prostate cancer
4. Older workers benefit from high-tech, high-touch health promotion
5. Too Much Information? Risk-benefit data does not always lead to informed decision-making
6. Scientists find potential benefit of hypericin for recurrent brain tumors
7. Pistachios deliver weight management support, heart health benefits
8. Children relate to stepparents based on perceived financial, emotional benefits, study finds
9. Does Stress Reduction Benefit Cancer Patients Health?
10. Results show benefits in using acute kidney injury criteria in the diagnosis of cirrhosis
11. Benefits of Radiation Therapy Outweigh Risks of a Second Cancer: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... ... February 11, 2016 , ... Dr. Sadati’s recent feature in ... Along with performing procedures, the magazine also highlights that Dr. Sadati has pioneered ... of the most common procedures he performs is his natural facelift. “As people ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... The president ... DoD Military Health System but would shift more of the cost burden to military ... TRICARE-reform plan laid out in the defense budget as including limited quantifiable benefit fixes ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... and women’s health, is pleased to announce the promotions of Allison Kelly to ... team, Steve Catone to executive vice president of North American capital sales, and ...
(Date:2/11/2016)... Laurel, NJ (PRWEB) , ... February 11, 2016 ... ... announces the call for nominations seeking candidates for the Board of Commissioners. Individuals ... with passion, skills and experience with diversity of clinical practice settings and across ...
(Date:2/11/2016)... , ... February 11, 2016 , ... ... of a master charity program created to assist the people of their local ... closely with nonprofit organizations and community leaders. Their hope is to bring awareness ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... SAN FRANCISCO , Feb. 11, 2016  Kindred ... focused on saving and improving the lives of pets, ... Technical Section of the New Animal Drug Application (NADA) ... the pivotal field study (KB0120) of Zimeta for the ... by the Company. --> ...
(Date:2/11/2016)... SAN FRANCISCO , Feb. 11, 2016   ... the advancement of new health technologies, announced today " ... outstanding achievements in health tech over the past ten ... For nearly a decade, Health 2.0 has served ... and showcased and connected with thousands of technologies, companies, ...
(Date:2/11/2016)... 11, 2016  MiMedx Group, Inc. (NASDAQ: MDXG ... membrane and other birth tissues, human skin and bone, ... market advanced products and therapies, announced today that it ... Healthcare Conference in New York , ... Michael J. Senken , Chief Financial Officer and ...
Breaking Medicine Technology: